Safety and efficacy of sorafenib for advanced hepatocellular carcinoma
Pc Sacco, M. Di Seri(Sapienza University of Rome), Silvia Quadrini(Policlinico Umberto I), M Tedeschi, Rita De Sanctis(Humanitas University), Paolo Grassi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alberto Fulvi, Pt Falbo, R. Sollami, Ester Del Signore(Policlinico Umberto I), Bruno Gori(Policlinico Umberto I), Basile Ml, Luciano Stumbo(Ospedale San Filippo Neri)
IRIS Research product catalog (Sapienza University of Rome)
January 1, 2009
Cited by 0
Related Papers
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy
|European Journal of Nuclear Medicine and Molecular Imaging|2019|150